EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

iRECIST: A Case Based Users Guide for Radiologists

Conor Waters iD, Darragh Halpenny

Canadian Association of Radiologists Journal · 2026

DOI: 10.1177/08465371251355866 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Canadian Association of Radiologists Journal, 2026. Verfasst von Conor Waters und 1 weiteren Autor:innen. Beteiligte Einrichtung: Tallaght University Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Response Evaluation Criteria in Solid Tumors, Immunotherapy, Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy with checkpoint inhibitors (ICI) has revolutionized oncology by stimulating the immune system to target cancer cells. While effective in treating various malignancies, ICI presents unique challenges in radiological response assessment. Traditional criteria, such as RECIST 1.1, were designed for cytotoxic chemotherapy and fail to account for pseudo-progression—an immune-related phenomenon where tumour size transiently increases due to immune cell infiltration before eventual shrinkage. This occurs in a minority of patients and can lead to misclassification of treatment response. To address this, new assessment criteria have been developed. The immune-related response criteria (irRC) introduced a delayed assessment of new lesions, followed by immune-related RECIST (irRECIST), which sought to align with RECIST 1.1. However, inconsistencies in its application led to the development of iRECIST in 2016, a standardized framework integrating RECIST 1.1 with immunotherapy-specific modifications. Despite its potential to become the gold standard, iRECIST is complex and challenging to implement consistently. This review outlines key differences between RECIST 1.1 and iRECIST, explains their necessity, and provides comprehensive flowcharts and graphical representations to aid interpretation. By addressing common clinical scenarios and frequently asked questions, this article aims to enhance understanding and application of iRECIST in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Response Evaluation Criteria in Solid TumorsImmunotherapyNeoplasmsImmune Checkpoint InhibitorsHumans

Stichwörter der Autor:innen

iRECISTimmunotherapyoncologyreporting

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Tallaght University Hospital, Dublin, Ireland.

ORCID-Profile: Conor Waters

Zitieren

APA

Waters, C., & Halpenny, D. (2026). iRECIST: A Case Based Users Guide for Radiologists. Canadian Association of Radiologists Journal. https://doi.org/10.1177/08465371251355866

Vancouver

Waters C, Halpenny D. iRECIST: A Case Based Users Guide for Radiologists. Canadian Association of Radiologists Journal. 2026. doi:10.1177/08465371251355866

BibTeX
@article{Waters2026,
  author = {Waters, Conor and Halpenny, Darragh},
  title = {iRECIST: A Case Based Users Guide for Radiologists},
  journal = {Canadian Association of Radiologists Journal},
  year = {2026},
  doi = {10.1177/08465371251355866}
}
Kostenlos starten →